未经治疗的根尖周炎与药物相关性颌骨坏死风险:系统综述及临床前研究机制见解
该系统综述纳入11项临床前动物研究,评估抗骨吸收治疗背景下未经治疗根尖周炎(AP)与药物相关性颌骨坏死(MRONJ)的关系。72.72%的研究在AP区域报告了MRONJ的组织学或临床证据,AP区域更频繁出现MRONJ。结论提示抗骨吸收治疗中未治AP可能增加MRONJ风险,需早期诊断管理牙髓感染。
要点
- 临床前证据显示抗骨吸收治疗下未治根尖周炎可能增加MRONJ风险。
- AP区域更频繁出现MRONJ,伴或不伴临床体征。
- 接受抗骨吸收治疗者应早期诊断和管理牙髓感染。
核心结论
- 临床前研究的系统综述表明,在抗骨吸收治疗背景下,未经治疗的根尖周炎可能增加MRONJ风险。
- 研究提供机制见解,阐明AP可能如何促进MRONJ发病机制,为临床观察提供理论背景。
- 人类研究提示潜在致病交互作用,但受限于异质性设计、口腔感染定义不一及AP常与其他情况合并分组。
- 结果强调接受抗骨吸收治疗患者(尤其暴露于更高累积剂量的癌症患者)早期诊断和管理牙髓感染的重要性。
- 需要设计良好的前瞻性临床研究确定AP是否为MRONJ的独立危险因素。
研究设计与样本
- 系统综述,检索PubMed/MEDLINE、Web of Science、Scopus和Embase,并用ProQuest评估灰色文献。
- 纳入标准:临床前研究;使用抗骨吸收、抗血管生成或其他已知致MRONJ药物;评估AP病变区域骨坏死发生的研究。
- 排除非动物研究。
- 从初始239条记录中纳入11项研究。
- 两名独立评审者进行数据提取和偏倚风险评估。
主要发现
- 根尖周病变诱导最常在双膦酸盐给药后进行。
- 唑来膦酸是最常用的药物。
- 72.72%的研究报告了未治AP区域MRONJ的组织学或临床证据。
- AP区域更频繁出现MRONJ,伴或不伴临床体征。
临床怎么用
- 对接受抗骨吸收治疗的患者,应早期诊断和管理牙髓感染以降低MRONJ风险。
- 尤其关注暴露于更高累积剂量的癌症患者。
局限性
- 纳入研究均为临床前动物研究,结果向人类转化需谨慎。
- 人类研究存在异质性设计、口腔感染定义不一及AP常与其他情况合并分组等局限。
- 需前瞻性临床研究验证AP是否为MRONJ独立危险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Medication-related osteonecrosis of the jaws (MRONJ) is a condition that causes progressive bone destruction and compromises patients' function, aesthetics, and quality of life. OBJECTIVES: This study aims to investigate the role of untreated apical periodontitis (AP) in the development of MRONJ. METHODS: A comprehensive search was performed in PubMed/MEDLINE, Web of Science, Scopus, and Embase. Gray literature was assessed using the ProQuest database. The eligibility criteria consisted of (1) preclinical studies; (2) use of antiresorptive, antiangiogenics, or other drugs known to cause MRONJ; (3) studies evaluating the development of osteonecrosis in regions of AP lesions. The following studies were excluded: (1) non-animal studies. Two independent reviewers performed data extraction and the assessment of the risk of bias. RESULTS: From an initial dataset of 239 records, we included 11 studies. Induction of periapical lesions was performed most often after the administration of bisphosphonates. Zoledronic acid was the most used drug. Histologic or clinical evidence of MRONJ in areas of untreated AP was reported in 72.72% of the studies. Furthermore, areas with AP presented MRONJ more frequently, with or without clinical signs. CONCLUSIONS: This systematic review of preclinical studies indicates that untreated AP, in the context of antiresorptive therapy, may increase the risk of MRONJ. Our findings provide mechanistic insights that clarify how AP may contribute to MRONJ pathogenesis, offering a theoretical background to support clinical observations. While human studies suggest a potential pathogenic interaction, they remain limited by heterogeneous designs, variable definitions of oral infections, and frequent grouping of AP with other conditions. These limitations underscore the translational significance of our preclinical analysis. Overall, our results reinforce the importance of early diagnosis and management of endodontic infections in patients receiving antiresorptive particularly cancer patients exposed to higher cumulative doses and highlight the need for well-designed prospective clinical studies to determine whether AP constitutes an independent risk factor for MRONJ.
引用
- Mota ME, Silva Lascane NA, Gimenez T, et al. Untreated Apical Periodontitis and the Risk of Medication-related Osteonecrosis of the Jaws (MRONJ): A Systematic Review with Mechanistic Insights from Preclinical Studies. J Endod. 2025. PMID: 41390055. doi:10.1016/j.joen.2025.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。